These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28299826)

  • 41. The role of the UKEMS in the development of testing guidelines.
    Kirkland DJ
    Mutagenesis; 2002 Nov; 17(6):451-5. PubMed ID: 12435841
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Strategy for genotoxicity testing--metabolic considerations.
    Ku WW; Bigger A; Brambilla G; Glatt H; Gocke E; Guzzie PJ; Hakura A; Honma M; Martus HJ; Obach RS; Roberts S;
    Mutat Res; 2007 Feb; 627(1):59-77. PubMed ID: 17141553
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of genetic toxicity data in GHS mutagenicity classification and labeling of substances.
    Ball NS; Hollnagel HM
    Environ Mol Mutagen; 2017 Jun; 58(5):354-360. PubMed ID: 28485542
    [TBL] [Abstract][Full Text] [Related]  

  • 44. International Cooperation on Harmonisation of Technical Requirements for Approval of Veterinary Medicinal Products (VICH); final guidance for industry on "studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing" (VICH GL23); availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jan; 67(3):602-3. PubMed ID: 12358039
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human biological relevance and the use of threshold-arguments in regulatory genotoxicity assessment: experience with pharmaceuticals.
    Müller L; Kasper P
    Mutat Res; 2000 Jan; 464(1):19-34. PubMed ID: 10633174
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relevance and follow-up of positive results in in vitro genetic toxicity assays: an ILSI-HESI initiative.
    Thybaud V; Aardema M; Casciano D; Dellarco V; Embry MR; Gollapudi BB; Hayashi M; Holsapple MP; Jacobson-Kram D; Kasper P; MacGregor JT; Rees R
    Mutat Res; 2007 Oct; 633(2):67-79. PubMed ID: 17616430
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Latest advances in computational genotoxicity prediction.
    Naven RT; Greene N; Williams RV
    Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1579-87. PubMed ID: 22998164
    [TBL] [Abstract][Full Text] [Related]  

  • 48. (Q)SAR assessments of potentially mutagenic impurities: a regulatory perspective on the utility of expert knowledge and data submission.
    Powley MW
    Regul Toxicol Pharmacol; 2015 Mar; 71(2):295-300. PubMed ID: 25545315
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genotoxicity risk assessment: a proposed classification strategy.
    Dearfield KL; Cimino MC; McCarroll NE; Mauer I; Valcovic LR;
    Mutat Res; 2002 Nov; 521(1-2):121-35. PubMed ID: 12438010
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of genetic toxicology information for risk assessment.
    Dearfield KL; Moore MM
    Environ Mol Mutagen; 2005 Dec; 46(4):236-45. PubMed ID: 16258925
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IWGT report on quantitative approaches to genotoxicity risk assessment II. Use of point-of-departure (PoD) metrics in defining acceptable exposure limits and assessing human risk.
    MacGregor JT; Frötschl R; White PA; Crump KS; Eastmond DA; Fukushima S; Guérard M; Hayashi M; Soeteman-Hernández LG; Johnson GE; Kasamatsu T; Levy DD; Morita T; Müller L; Schoeny R; Schuler MJ; Thybaud V
    Mutat Res Genet Toxicol Environ Mutagen; 2015 May; 783():66-78. PubMed ID: 25953401
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prediction of genotoxic potential of cosmetic ingredients by an in silico battery system consisting of a combination of an expert rule-based system and a statistics-based system.
    Aiba née Kaneko M; Hirota M; Kouzuki H; Mori M
    J Toxicol Sci; 2015 Feb; 40(1):77-98. PubMed ID: 25743748
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Strategies and testing methods for identifying mutagenic risks.
    MacGregor JT; Casciano D; Müller L
    Mutat Res; 2000 Nov; 455(1-2):3-20. PubMed ID: 11113464
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genotoxicity and carcinogenicity studies of bronchodilators and antiasthma drugs.
    Brambilla G; Mattioli F; Robbiano L; Martelli A
    Basic Clin Pharmacol Toxicol; 2013 May; 112(5):302-13. PubMed ID: 23374861
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative overview of current international strategies and guidelines for genetic toxicology testing for regulatory purposes.
    Cimino MC
    Environ Mol Mutagen; 2006 Jun; 47(5):362-90. PubMed ID: 16649190
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the LacZ reporter assay in cryopreserved primary hepatocytes for In vitro genotoxicity testing.
    Luijten M; Zwart EP; Dollé ME; de Pooter M; Cox JA; White PA; van Benthem J
    Environ Mol Mutagen; 2016 Dec; 57(9):643-655. PubMed ID: 27859631
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-specificity and high-sensitivity genotoxicity assessment in a human cell line: validation of the GreenScreen HC GADD45a-GFP genotoxicity assay.
    Hastwell PW; Chai LL; Roberts KJ; Webster TW; Harvey JS; Rees RW; Walmsley RM
    Mutat Res; 2006 Sep; 607(2):160-75. PubMed ID: 16781187
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bacterial mutagenicity assays: Vehicle and positive control results from the standard Ames assay, the 6- and 24-well miniaturized plate incorporation assays and the Ames II™ assay.
    Pant K; Bruce S; Sly J; Klug Laforce M; Springer S; Cecil M; Andrus E; Dakoulas E; Wagner VO; Hewitt NJ; Kulkarni R
    Environ Mol Mutagen; 2016 Jul; 57(6):483-96. PubMed ID: 27198925
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genotoxicity Assessment of Drug Metabolites in the Context of MIST and Beyond.
    Zeller A; Brigo A; Brink A; Guerard M; Lang D; Muster W; Runge F; Sutter A; Vock E; Wichard J; Schadt S
    Chem Res Toxicol; 2020 Jan; 33(1):10-19. PubMed ID: 31859487
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development.
    Dobo KL; Greene N; Cyr MO; Caron S; Ku WW
    Regul Toxicol Pharmacol; 2006 Apr; 44(3):282-93. PubMed ID: 16464524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.